Financials • Investment Managers
$72.91 ▲ +2.86
(+4.08%)
MKT CAP: $3.75B • VOL: 181.2K
52W L $58 52W H $87
ROARABLE / RQD
D • 48/100
PIOTROSKI
2 / 9
CNS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $177.7M | $172.9M | $164.5M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | $153.2M | $151.3M | $129.0M |
| EBITDA (Normalized) | $182.5M | $182.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$120.4M | $96.7M | $172.0M |
| Capital Expenditures (CapEx) | $6.0M | $11.7M | — |
| Free Cash Flow (FCF) | -$126.4M | $85.0M | $172.0M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | 33.7% | 41.5% | — |
| Cash & Short-Term Equivalents | $145.5M | $183.0M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $562.0M | $511.7M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CNS.